Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.19 Million SEK | -65.91% |
| 2022 | 41.64 Million SEK | -8.59% |
| 2021 | 45.55 Million SEK | 49.5% |
| 2020 | 30.47 Million SEK | -3.79% |
| 2019 | 31.67 Million SEK | 285.61% |
| 2018 | 8.21 Million SEK | -31.22% |
| 2017 | 11.94 Million SEK | 16.62% |
| 2016 | 10.23 Million SEK | 264.82% |
| 2015 | 2.8 Million SEK | -47.82% |
| 2014 | 5.37 Million SEK | 72.97% |
| 2013 | 3.1 Million SEK | 4.77% |
| 2012 | 2.96 Million SEK | 36.49% |
| 2011 | 2.17 Million SEK | 54.76% |
| 2010 | 1.4 Million SEK | -10.71% |
| 2009 | 1.57 Million SEK | -14.73% |
| 2008 | 1.84 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 11.37 Million SEK | -19.86% |
| 2024 Q3 | 10.28 Million SEK | -54.45% |
| 2024 Q2 | 22.57 Million SEK | 98.42% |
| 2023 Q1 | 37.46 Million SEK | -10.04% |
| 2023 Q4 | 14.19 Million SEK | 40.47% |
| 2023 FY | 14.19 Million SEK | -65.91% |
| 2023 Q3 | 10.1 Million SEK | -82.59% |
| 2023 Q2 | 58.06 Million SEK | 55.01% |
| 2022 Q1 | 48.62 Million SEK | 6.73% |
| 2022 Q4 | 41.64 Million SEK | -7.95% |
| 2022 Q3 | 45.23 Million SEK | -11.16% |
| 2022 FY | 41.64 Million SEK | -8.59% |
| 2022 Q2 | 50.91 Million SEK | 4.73% |
| 2021 Q1 | 44.71 Million SEK | 46.74% |
| 2021 Q3 | 41.52 Million SEK | -6.99% |
| 2021 Q4 | 45.55 Million SEK | 9.7% |
| 2021 FY | 45.55 Million SEK | 49.5% |
| 2021 Q2 | 44.64 Million SEK | -0.15% |
| 2020 Q3 | 29.05 Million SEK | -1.89% |
| 2020 FY | 30.47 Million SEK | -3.79% |
| 2020 Q1 | 28.64 Million SEK | -9.56% |
| 2020 Q2 | 29.61 Million SEK | 3.4% |
| 2020 Q4 | 30.47 Million SEK | 4.88% |
| 2019 FY | 31.67 Million SEK | 285.61% |
| 2019 Q2 | 29.25 Million SEK | 336.2% |
| 2019 Q3 | 27.38 Million SEK | -6.39% |
| 2019 Q4 | 31.67 Million SEK | 15.63% |
| 2019 Q1 | 6.7 Million SEK | -18.34% |
| 2018 Q1 | 6.56 Million SEK | -44.99% |
| 2018 Q4 | 8.21 Million SEK | 42.53% |
| 2018 Q3 | 5.76 Million SEK | -17.43% |
| 2018 Q2 | 6.97 Million SEK | 6.25% |
| 2018 FY | 8.21 Million SEK | -31.22% |
| 2017 Q2 | 7.31 Million SEK | -34.66% |
| 2017 Q1 | 11.19 Million SEK | 9.36% |
| 2017 FY | 11.94 Million SEK | 16.62% |
| 2017 Q4 | 11.94 Million SEK | 72.68% |
| 2017 Q3 | 6.91 Million SEK | -5.48% |
| 2016 FY | 10.23 Million SEK | 264.82% |
| 2016 Q4 | 10.23 Million SEK | -7.62% |
| 2016 Q1 | 7.78 Million SEK | 177.54% |
| 2016 Q3 | 11.08 Million SEK | 229.71% |
| 2016 Q2 | 3.36 Million SEK | -56.85% |
| 2015 Q1 | 3.46 Million SEK | -35.65% |
| 2015 FY | 2.8 Million SEK | -47.82% |
| 2015 Q4 | 2.8 Million SEK | 9.41% |
| 2015 Q3 | 2.56 Million SEK | 5.03% |
| 2015 Q2 | 2.44 Million SEK | -29.43% |
| 2014 Q2 | 2.37 Million SEK | -15.73% |
| 2014 Q4 | 5.37 Million SEK | 120.22% |
| 2014 Q3 | 2.44 Million SEK | 3.05% |
| 2014 FY | 5.37 Million SEK | 72.97% |
| 2014 Q1 | 2.81 Million SEK | -9.54% |
| 2013 Q3 | 8.88 Million SEK | 46.19% |
| 2013 Q4 | 3.1 Million SEK | -65.01% |
| 2013 FY | 3.1 Million SEK | 4.77% |
| 2013 Q1 | 3.03 Million SEK | 2.41% |
| 2013 Q2 | 6.07 Million SEK | 99.96% |
| 2012 FY | 2.96 Million SEK | 36.49% |
| 2012 Q4 | 2.96 Million SEK | 16.89% |
| 2012 Q2 | 1.58 Million SEK | -14.28% |
| 2012 Q3 | 2.53 Million SEK | 60.31% |
| 2012 Q1 | 1.84 Million SEK | -15.03% |
| 2011 Q3 | 1.49 Million SEK | -12.03% |
| 2011 Q4 | 2.17 Million SEK | 45.68% |
| 2011 Q1 | 1.39 Million SEK | -0.77% |
| 2011 FY | 2.17 Million SEK | 54.76% |
| 2011 Q2 | 1.69 Million SEK | 21.7% |
| 2010 Q4 | 1.4 Million SEK | 13.59% |
| 2010 Q1 | 1.62 Million SEK | 3.47% |
| 2010 Q2 | 1.54 Million SEK | -4.91% |
| 2010 FY | 1.4 Million SEK | -10.71% |
| 2010 Q3 | 1.23 Million SEK | -20.1% |
| 2009 Q3 | 1.34 Million SEK | -15.69% |
| 2009 FY | 1.57 Million SEK | -14.73% |
| 2009 Q4 | 1.57 Million SEK | 16.59% |
| 2009 Q2 | 1.6 Million SEK | 0.0% |
| 2008 Q4 | 1.84 Million SEK | 0.0% |
| 2008 FY | 1.84 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -29.087% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.469% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.469% |
| Arcoma AB | 33.3 Million SEK | 57.373% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 95.694% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.565% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 94.928% |
| CellaVision AB (publ) | 212.32 Million SEK | 93.313% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -106.684% |
| C-Rad AB (publ) | 122.4 Million SEK | 88.401% |
| Duearity AB (publ) | 17.53 Million SEK | 19.013% |
| Dignitana AB (publ) | 37.56 Million SEK | 62.209% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 28.298% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.943% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 31.084% |
| Iconovo AB (publ) | 14.55 Million SEK | 2.452% |
| Integrum AB (publ) | 22.07 Million SEK | 35.681% |
| Luxbright AB (publ) | 7 Million SEK | -102.811% |
| Mentice AB (publ) | 163.55 Million SEK | 91.32% |
| OssDsign AB (publ) | 105.25 Million SEK | 86.512% |
| Paxman AB (publ) | 44.5 Million SEK | 68.103% |
| Promimic AB (publ) | 16.15 Million SEK | 12.126% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 77.164% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 33.279% |
| ScandiDos AB (publ) | 37.18 Million SEK | 61.822% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.135% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 67.779% |
| Senzime AB (publ) | 58.06 Million SEK | 75.55% |
| SpectraCure AB (publ) | 14.97 Million SEK | 5.195% |
| Stille AB | 172.64 Million SEK | 91.777% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.613% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 94.334% |